Strongbridge Biopharma PLC (SBBP)
Stock Price:
$3.99 USD
0.01 (0.25%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
216.88M |
| Revenue (ttm) |
25.72M |
| Net Income (ttm) |
-52.74M |
| Shares Out |
54.36M |
| EPS (ttm) |
-1.05 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$3.99 |
| Previous Close |
$3.98 |
| Change ($) |
0.01 |
| Change (%) |
0.25% |
| Day's Open |
3.99 |
| Day's Range |
3.75 - 4.16 |
| Day's Volume |
1,092,229 |
| 52-Week Range |
1.43 - 4.63 |
More Stats
| Market Cap |
216.88M |
| Enterprise Value |
163.97M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
54.36M |
| Float |
26.92M |
| EPS (basic) |
-0.96 |
| EPS (diluted) |
-1.05 |
| FCF / Share |
-0.66 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
684,042 |
| Short Ratio |
1.51 |
| Short % of Float |
1.27% |
| Beta |
4.69 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
8.43 |
| PB Ratio |
4.53 |
| Revenue |
25.72M |
| Operating Income |
-56.75M |
| Net Income |
-52.74M |
| Free Cash Flow |
-35.79M |
| Net Cash |
52.91M |
| Net Cash / Share |
0.97 |
| Gross Margin |
69.55% |
| Operating Margin |
-220.61% |
| Profit Margin |
-205.00% |
| FCF Margin |
-139.13% |
| ROA |
-28.42% |
| ROE |
-75.80% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$8.33*
(108.77% upside)
Low
5.00
Current: $3.99
High
18.00
Target: 8.33
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 21.71 | 18.03 | 7.05 | - | - | - | - |
| Revenue Growth | 20.44% | 155.85% | - | - | - | - | - |
| Gross Profit | 17.89 | 14.04 | 5.56 | - | - | - | - |
| Operating Income | -67.09 | -81.92 | -73.74 | -50.73 | -42.85 | -10.43 | -5.19 |
| Net Income | -49.45 | 31.85 | -113 | -48.60 | -43.58 | -9.67 | -5.30 |
| Shares Outstanding | 54.18 | 46.30 | 36.54 | 21.55 | 16.61 | 8.04 | 6.02 |
| Earnings Per Share | -0.91 | 0.69 | -3.11 | -2.27 | -2.62 | -1.20 | -0.88 |
| Operating Cash Flow | -44.78 | -84.58 | -45.34 | -31.71 | -37.36 | -9.50 | -3.48 |
| Capital Expenditures | -0.07 | -0.33 | - | - | -0.03 | -0.02 | - |
| Free Cash Flow | -44.86 | -84.90 | -45.34 | -31.71 | -37.39 | -9.53 | -3.48 |
| Cash & Equivalents | 78.10 | 122 | 57.51 | 66.84 | 51.62 | 15.63 | 14.90 |
| Total Debt | - | - | 37.79 | 18.43 | - | - | - |
| Net Cash / Debt | 78.10 | 122 | 19.72 | 48.40 | 51.62 | 15.63 | 14.90 |
| Assets | 118 | 170 | 104 | 138 | 97.33 | 23.69 | 22.57 |
| Liabilities | 45.45 | 57.33 | 116 | 70.56 | 6.40 | 4.87 | 4.75 |
| Book Value | 72.19 | 113 | -11.91 | 66.97 | 90.36 | 18.82 | 17.80 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Strongbridge Biopharma PLC |
| Country |
United States |
| Employees |
71 |
| CEO |
John H. Johnson |
Stock Information
| Ticker Symbol |
SBBP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SBBP |
| IPO Date |
October 16, 2015 |
Description
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.